MatkoKalacMD

PubMed

• CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma.
  Tyler D'Ovidio, Kathryn Ciccolini, Matko Kalac, Keren Osman, Amir Steinberg> ;Cureus. 2023 Sep 1
• Idiopathic CD4+ T-lymphocytopaenia withmutation complicated by progressive multifocal leucoencephalopathy and EBV+ polymorphic lymphoproliferative disorder.
  Noa Rippel, Joshua Wong, Shafinaz Hussein, Matko Kalac> ;BMJ Case Reports. 2023 Aug 29
• 1 citations
  Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma.
  Matko Kalac, Salvia Jain, Constantine S Tam, Zhengrui Xiao, Francesca Montanari, Jennifer Kanakry, Bryan D Huber, Mendel Goldfinger, Owen A O'Connor, Enrica Marchi> ;Blood Advances. 2023 Jul 25
• N-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-κB.
  Matko Kalac, Michael Mangone, Alison Rinderspacher, Shi-Xian Deng, Luigi Scotto, Michael Markson, Mukesh Bansal, Andrea Califano, Donald W. Landry, Owen A. O'Connor> ;Iscience. 2020 Nov 30
• 2 citations
  Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma.
  Kyle Farina, Matko Kalac, Sara Kim> ;Journal of Oncology Pharmacy Practice. 2021 Jun 1
• 19 citations
  Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL)
  Xin Xu, Matko Kalac, Michael Markson, Mark Chan, Joshua Brody, Govind Bhagat, Rosalind L. Ang, Diana Legarda, Scott J. Justus, Feng Liu, Qingshan Li, Huabao Xiong, Adr...> ;Cell Death & Disease. 2020 Feb 5
• 11 citations
  Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
  Matko Kalac, Jennifer K. Lue, Emily Lichtenstein, Ithamar Turenne, Celeste Rojas, Jennifer E Amengual, Ahmed Sawas, Changchun Deng, Markus Y. Mapara, Joseph M. Connors...> ;British Journal of Haematology. 2018 Mar 1
• 86 citations
  A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
  Jennifer E Amengual, Renee Lichtenstein, Jennifer K. Lue, Ahmed Sawas, Changchun Deng, Emily Lichtenstein, Karen Khan, Laine Atkins, Aishling M. Rada, Hye A. Kim, Codr...> ;Blood. 2018 Jan 25
• 70 citations
  Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial
  Owen A. O'Connor, Jennifer K. Lue, Ahmed Sawas, Jennifer E Amengual, Changchun Deng, Matko Kalac, Lorenzo Falchi, Enrica Marchi, Ithamar Turenne, Renee Lichtenstein, C...> ;The Lancet. Oncology. 2017 Dec 1
• 2 citations
  An Update on the Use of Immunotherapy in the Treatment of Lymphoma.
  Thomas U. Marron, Matko Kalac, Joshua Brody> ;Current Hematologic Malignancy Reports. 2017 Jul 22
• 44 citations
  The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma.
  Enrica Marchi, Kelly Zullo, Jennifer E Amengual, Matko Kalac, Danielle C Bongero, Christine McIntosh, Laura K Fogli, Maura Rossi, Pier Luigi Zinzani, Stefano Pileri, P...> ;British Journal of Haematology. 2015 Oct 1
• 45 citations
  Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action.
  Coral Omene, Matko Kalac, Jing Wu, Enrica Marchi, Krystyna Frenkel, Owen A. O'Connor> ;Journal of Cancer Science & Therapy. 2013 Oct 21
• 46 citations
  Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma
  Jennifer E Amengual, Sean Clark-Garvey, Matko Kalac, Luigi Scotto, Enrica Marchi, Ellen Neylon, Paul Johannet, Ying Wei, Jasmine Zain, Owen A. O'Connor> ;Blood. 2013 Sep 19
• 10 citations
  Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
  Luigi Scotto, Marianna Kruithof-de Julio, Luca Paoluzzi, Matko Kalac, Enrica Marchi, Jairo Baquero Buitrago, Jennifer E Amengual, Michael M. Shen, Owen A. O'Connor> ;Clinical Cancer Research. 2012 Jul 15
• 110 citations
  HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
  Matko Kalac, Luigi Scotto, Enrica Marchi, Jennifer E Amengual, Venkatraman E. Seshan, Govind Bhagat, Netha Ulahannan, Violetta V. Leshchenko, Alexis Temkin, Samir Pare...> ;Blood. 2011 Nov 17
• Autologous stem cell transplantation in patients with relapsed or refractory Hodgkin's disease
  Hrvoje Minigo, Radovan Vrhovac, Matko Kalac, Branimir Jakšić> ;Acta Medica Croatica. 2009 Jan 1
• 6 citations
  New Drugs for the Treatment of Lymphoma
  Luca Paoluzzi, Yukiko Kitagawa, Matko Kalac, Jasmine Zain, Owen A. O'Connor> ;Hematology/oncology Clinics of North America. 2008 Oct 1
• 21 citations
  A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia
  Matko Kalac, Alfonso Quintás-Cardama, Radovan Vrhovac, Hagop M. Kantarjian, Srdan Verstovsek> ;Cancer. 2007 Sep 1
• 2 citations
  The disappearance of CD20 positive lymphocytes in the pleural effusion after intrapleural application of rituximab
  Matko Kalac, Slobodanka Ostojić Kolonić, Ika Kardum-Skelin, Ana Planinc-Peraica, Zoran Šiftar, Branimir Jakšić> ;Acta Medica Croatica. 2007 Sep 1
• 1 citations
  [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report].
  Matko Kalac, Slobodanka Ostojić, Slavko Gašparov, Ana Planinc-Peraica, Marija Dominis, Branimir Jakšić> ;Lijecnicki Vjesnik. 2006 Mar 1
• Central nervous system involvement of previously undiagnosed chronic lymphocytic leukemia in a patient with neuroborreliosis.
  Kalac, M., Suvic-Krizanic, V., Ostojic, S., Kardum-Skelin, I., Barsic, B., Jaksica, B.> ;Int J Hematol. 2007 May
• Join now to see all

Journal Articles

• Brentuximab Vedotin and Bendamustine Produce High Complete Response Rates in Patients with Chemotherapy Refractory Hodgkin Lymphoma  
  Changchun Deng, Markus Y. Mapara, Ahmed Sawas, Matko Kalac, British Journal of Haematology

Lectures

• Constitutive Phosphorylation of CYLD Promotes ATLL Survival By Inhibiting RIPK1-Dependent Cell Death 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018